Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

RUNX3 Has an Oncogenic Role in Head and Neck Cancer

Figure 6

RUNX3 overexpression inhibited chemotherpeutic drug induced apoptosis.

A: Adriamycin (Dox, 0, 0.5 and 1 µg/ml) was treated for 72 hours in control and RUNX3 overexpressing HSC3 cells. Cell cycle distribution was determined by DNA content analysis after propidium iodide staining using a flow cytometer. For each sample, 20,000 events were stored. Percentage of sub-G1 population is indicated. We performed two independent experiments with triplicate wells per condition. Representative data is shown. B: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 overexpressing cells after DOX treatment for 72 h at the indicated doses. C: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 knockdown cells after DOX treatment for 72 h at the indicated doses. We performed two independent experiments.

Figure 6

doi: https://doi.org/10.1371/journal.pone.0005892.g006